Phoenix Biotech Acquisition - Units (1 Ord Class A & 1/2 War) Accounts Payable

As of the most recent data (June 2026), PBAXU shows a accounts payable of $8.2M. That compares with $6.2M in the prior-year period — up 32.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PBAXU's accounts payable is now $8.2M (was $6.2M) — a 32.3% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Phoenix Biotech Acquisition - Units (1 Ord Class A & 1/2 War) is outperforming or lagging.

Tracking PBAXU's accounts payable over time shows whether Phoenix Biotech Acquisition - Units (1 Ord Class A & 1/2 War) is scaling, shrinking, or reshaping that part of the business. The current reading is $8.2M That compares with $6.2M in the prior-year period — up 32.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Phoenix Biotech Acquisition - Units (1 Ord Class A & 1/2 War)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $8.2M) with ownership activity and broader fundamentals.